PDCD1 and neoplasm: Data from 12 NSCLC patients suggested that multiple non-mutated neoantigens released from cisplatin-induced apoptotic tumor cells elicited CD8+ or CD4+ Teff cell responses, which could notably be promoted by anti-PD-1 therapy, correlating with OS (167).